Application of a PBPK model for prediction of the DDI between Lorazepam and Probenecid. ポスター Application of a PBPK model for prediction of the DDI between Lorazepam and Probenecid. webdev2019年8月22日
What Sample Size to Use When Designing Paediatric Pharmacokinetic Studies? A Critical Analysis of “Precision Criteria” Poster What Sample Size to Use When Designing Paediatric Pharmacokinetic Studies? A Critical Analysis of “Precision Criteria” webdev2019年8月22日
T4.1 – Setting the framework for database and development of this database Poster T4.1 – Setting the framework for database and development of this database webdev2019年8月22日
Modelling Toxicodynamic Feedback is Critical in Recovering Toxicokinetics in Acetaminophen Overdose Poster Modelling Toxicodynamic Feedback is Critical in Recovering Toxicokinetics in Acetaminophen Overdose webdev2019年8月9日
Development and Performance Evaluation of a semi-mechanistic PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eye Poster Development and Performance Evaluation of a semi-mechanistic PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eye webdev2019年6月24日
Transporter inhibition: modelling in-vitro Transwell Assays Poster Transporter inhibition: modelling in-vitro Transwell Assays webdev2019年6月24日
Optimize Immuno-oncology Drug Discovery and Development Using QSP White Paper がん免疫療法の創薬と開発をQSPで最適化 A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to…webdev2019年6月19日
Pirana Modeling Workbench Brochure Pirana モデリングワークベンチ Pirana is a flexible and extendible modeling workbench with an intuitive graphical user interface for…webdev2019年5月28日
Precision Dosing in Clinical Medicine: Present and Future Publication Precision Dosing in Clinical Medicine: Present and Future webdev2018年7月20日
Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond Publication Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…Jieun Choe2018年6月2日